0.70 USD
▼-0.09-11.03%
盘后 0.69 -1.79%
2026-11-20
市值
$3.10M
市盈率
—
EPS
-7.59
股息率
—
52 周区间
0.48 – 11.04
成交量
289.02K
Beta
3.15
目标价
9.00
52W 低 0.4852W 高 11.04
价格走势
公司简介
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses met...